Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Biol Chem
2022 Jan 01;2981:101455. doi: 10.1016/j.jbc.2021.101455.
Show Gene links
Show Anatomy links
Assessing potentiation of the (α4)3(β2)2 nicotinic acetylcholine receptor by the allosteric agonist CMPI.
Deba F
,
Munoz K
,
Peredia E
,
Akk G
,
Hamouda AK
.
???displayArticle.abstract???
The extracellular domain of the nicotinic acetylcholine receptor isoforms formed by three α4 and two β2 subunits ((α4)3(β2)2 nAChR) harbors two high-affinity "canonical" acetylcholine (ACh)-binding sites located in the two α4:β2 intersubunit interfaces and a low-affinity "noncanonical" ACh-binding site located in the α4:α4 intersubunit interface. In this study, we used ACh, cytisine, and nicotine (which bind at both the α4:α4 and α4:β2 interfaces), TC-2559 (which binds at the α4:β2 but not at the α4:α4 interface), and 3-(2-chlorophenyl)-5-(5-methyl-1-(piperidin-4-yl)-1H-pyrrazol-4-yl)isoxazole (CMPI, which binds at the α4:α4 but not at the α4:β2 interface), to investigate the binding and gating properties of CMPI at the α4:α4 interface. We recorded whole-cell currents from Xenopus laevis oocytes expressing (α4)3(β2)2 nAChR in response to applications of these ligands, alone or in combination. The electrophysiological data were analyzed in the framework of a modified Monod-Wyman-Changeux allosteric activation model. We show that CMPI is a high-affinity, high-efficacy agonist at the α4:α4 binding site and that its weak direct activating effect is accounted for by its inability to productively interact with the α4:β2 sites. The data presented here enhance our understanding of the functional contributions of ligand binding at the α4:α4 subunit interface to (α4)3(β2)2 nAChR-channel gating. These findings support the potential use of α4:α4 specific ligands to increase the efficacy of the neurotransmitter ACh in conditions associated with decline in nAChRs activity in the brain.
Albrecht,
Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiators.
2008, Pubmed
Albrecht,
Discovery and optimization of substituted piperidines as potent, selective, CNS-penetrant alpha4beta2 nicotinic acetylcholine receptor potentiators.
2008,
Pubmed
Benallegue,
The additional ACh binding site at the α4(+)/α4(-) interface of the (α4β2)2α4 nicotinic ACh receptor contributes to desensitization.
2013,
Pubmed
,
Xenbase
Carbone,
Pentameric concatenated (alpha4)(2)(beta2)(3) and (alpha4)(3)(beta2)(2) nicotinic acetylcholine receptors: subunit arrangement determines functional expression.
2009,
Pubmed
,
Xenbase
Changeux,
Nicotine addiction and nicotinic receptors: lessons from genetically modified mice.
2010,
Pubmed
Changeux,
Allosteric receptors: from electric organ to cognition.
2010,
Pubmed
Connolly,
Alpha 4-2 beta 2 and other nicotinic acetylcholine receptor subtypes as targets of psychoactive and addictive drugs.
1992,
Pubmed
,
Xenbase
Dani,
Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system.
2007,
Pubmed
DeDominicis,
The (α4)3(β2)2 Stoichiometry of the Nicotinic Acetylcholine Receptor Predominates in the Rat Motor Cortex.
2017,
Pubmed
Deba,
LY2087101 and dFBr share transmembrane binding sites in the (α4)3(β2)2 Nicotinic Acetylcholine Receptor.
2018,
Pubmed
,
Xenbase
Eaton,
Multiple Non-Equivalent Interfaces Mediate Direct Activation of GABAA Receptors by Propofol.
2016,
Pubmed
Forman,
Monod-Wyman-Changeux allosteric mechanisms of action and the pharmacology of etomidate.
2012,
Pubmed
Giniatullin,
Rapid relief of block by mecamylamine of neuronal nicotinic acetylcholine receptors of rat chromaffin cells in vitro: an electrophysiological and modeling study.
2000,
Pubmed
Gotti,
Neuronal nicotinic receptors: from structure to pathology.
2004,
Pubmed
Grupe,
Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors.
2013,
Pubmed
Hamouda,
Photolabeling a Nicotinic Acetylcholine Receptor (nAChR) with an (α4)3(β2)2 nAChR-Selective Positive Allosteric Modulator.
2016,
Pubmed
,
Xenbase
Hamouda,
Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms.
2021,
Pubmed
Harpsøe,
Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors.
2011,
Pubmed
Hurst,
Nicotinic acetylcholine receptors: from basic science to therapeutics.
2013,
Pubmed
Indurthi,
Ligand Binding at the 4-4 Agonist-Binding Site of the 42 nAChR Triggers Receptor Activation through a Pre-Activated Conformational State.
2016,
Pubmed
,
Xenbase
Jensen,
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
2005,
Pubmed
Kim,
Synthesis of desformylflustrabromine and its evaluation as an alpha4beta2 and alpha7 nACh receptor modulator.
2007,
Pubmed
,
Xenbase
Lester,
Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery.
2009,
Pubmed
Li,
The neuronal nicotinic alpha4beta2 receptor has a high maximal probability of being open.
2010,
Pubmed
MONOD,
ON THE NATURE OF ALLOSTERIC TRANSITIONS: A PLAUSIBLE MODEL.
1965,
Pubmed
Marks,
Two pharmacologically distinct components of nicotinic receptor-mediated rubidium efflux in mouse brain require the beta2 subunit.
1999,
Pubmed
Mazzaferro,
Potentiation of a neuronal nicotinic receptor via pseudo-agonist site.
2019,
Pubmed
Mazzaferro,
Non-equivalent ligand selectivity of agonist sites in (α4β2)2α4 nicotinic acetylcholine receptors: a key determinant of agonist efficacy.
2014,
Pubmed
,
Xenbase
Mohamed,
Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation.
2015,
Pubmed
Moroni,
Stoichiometry and pharmacology of two human alpha4beta2 nicotinic receptor types.
2006,
Pubmed
,
Xenbase
Nelson,
Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors.
2003,
Pubmed
,
Xenbase
Olsen,
Structural and functional studies of the modulator NS9283 reveal agonist-like mechanism of action at α4β2 nicotinic acetylcholine receptors.
2014,
Pubmed
,
Xenbase
Peters,
Prenylated indole alkaloids from Flustra foliacea with subtype specific binding on NAChRs.
2004,
Pubmed
Richter,
Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site ligands.
2012,
Pubmed
Sala,
Potentiation of human alpha4beta2 neuronal nicotinic receptors by a Flustra foliacea metabolite.
2005,
Pubmed
,
Xenbase
Sine,
Agonists block currents through acetylcholine receptor channels.
1984,
Pubmed
Springer,
Synthesis and activity of substituted carbamates as potentiators of the alpha4beta2 nicotinic acetylcholine receptor.
2008,
Pubmed
Srinivasan,
Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning.
2011,
Pubmed
Steinbach,
Applying the Monod-Wyman-Changeux Allosteric Activation Model to Pseudo-Steady-State Responses from GABAA Receptors.
2019,
Pubmed
Taly,
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.
2009,
Pubmed
Timmermann,
Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.
2012,
Pubmed
,
Xenbase
Vallejo,
Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism.
2005,
Pubmed
Walsh,
Structural principles of distinct assemblies of the human α4β2 nicotinic receptor.
2018,
Pubmed
Wang,
Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.
2018,
Pubmed
Wang,
Unraveling amino acid residues critical for allosteric potentiation of (α4)3(β2)2-type nicotinic acetylcholine receptor responses.
2017,
Pubmed
,
Xenbase
Wang,
An Accessory Agonist Binding Site Promotes Activation of α4β2* Nicotinic Acetylcholine Receptors.
2015,
Pubmed
,
Xenbase
Weltzin,
Desformylflustrabromine Modulates α4β2 Neuronal Nicotinic Acetylcholine Receptor High- and Low-Sensitivity Isoforms at Allosteric Clefts Containing the β2 Subunit.
2015,
Pubmed
,
Xenbase
